*Varun Beverages Ltd* is one of the largest franchisee bottlers for PepsiCo globally, operating in India and several international markets. It manufactures and distributes carbonated soft drinks, juices, and packaged drinking water under PepsiCo brands like Pepsi, Mirinda, 7UP, and Aquafina. Founded in 1995, VBL is headquartered in Gurgaon, India, and has expanded through strategic acquisitions and new territories, including Sri Lanka, Nepal, and parts of Africa. Its business model focuses on high-volume sales, particularly in the peak summer season (Q1 and Q2 in India), and it emphasizes operational efficiency and sustainability. History of Varun Beverages Ltd • 1995: Incorporated as a private company. • 2016: Listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) under ticker VBL. • 2017–2023: Issued multiple bonuses and stock splits, reducing share price to enhance liquidity and reflecting strong growth. Posts on X note no 20% correction since 2017, indicating consistent stock performance. • Expansion: Expanded into new territories like Meghalaya and Sri Lanka, boosting production capacity. By 2025, VBL operates over 40 manufacturing facilities across India and internationally. • Sustainability: Invested in eco-friendly initiatives, such as reducing plastic usage and improving water efficiency, aligning with PepsiCo’s global sustainability goals. • Financial Growth: Achieved a compounded annual growth rate (CAGR) of 78–80% in stock value, driven by strong sales and profit growth. Q4 Result Analysis for Varun Beverages Ltd Since specific Q4 2024 financial results for Varun Beverages Ltd are not provided in the sources, I’ll rely on available data from earlier quarters and posts on X to give a general analysis, focusing on trends and the most recent insights. For precise Q4 2024 data, you may need to check VBL’s official investor releases or financial platforms like BSE or Moneycontrol. • Recent Performance (Q1 2025 Context): A post on X from June 2025 highlights a 33.45% profit rise and 30.1% volume growth in Q1 2025, with analysts like Goldman Sachs bullish on VBL’s outlook due to expansion and strong fundamentals. This suggests VBL’s growth momentum likely carried into Q4 2024, though Q4 is typically a weaker quarter due to lower beverage demand in winter. • Historical Q4 Trends: Q4 is not VBL’s strongest quarter, as noted in an X post stating Q1 is the strongest due to seasonal demand. For example, Q4 2021 PAT was ₹271 crore compared to ₹802 crore in Q1 2022, reflecting seasonality. • Key Metrics (Based on Q1 2022 and Recent Trends): ◦ Revenue: In Q1 2022, revenue grew 100% YoY to ₹5,017 crore. Similar growth is likely moderated in Q4 due to seasonality, but expansion into new markets may have sustained strong revenue. ◦ Profit After Tax (PAT): Q1 2025 showed a 33.45% PAT increase. Q4 PAT is typically lower, but improved margins and debt reduction (noted in Q1 2022) suggest resilience. ◦ EBITDA Margins: Q1 2022 reported 25.2% margins, up YoY, driven by higher realizations (2.7% increase) and operational efficiency. ◦ Earnings Per Share (EPS): Q1 2025 EPS grew 30% QoQ and 291% YoY, indicating robust per-share profitability. ◦ Debt Reduction: VBL reduced debt significantly, improving financial health. • Valuation: X posts highlight an attractive P/E ratio and DIIs increasing stakes, reflecting investor confidence. • Challenges: Seasonality impacts Q4 performance, and rising raw material costs or currency fluctuations in international markets could pressure margins. About VBL Therapeutics If you meant VBL Therapeutics (NASDAQ: VBLT), here’s a brief overview based on the provided web results: • Overview: VBL Therapeutics, based in Modi’in, Israel, is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and immune-inflammatory diseases. Founded in 2000, it was publicly traded until its merger with Notable Labs in October 2023. • Key Products: ◦ VB-111 (Ofra-vec): A gene-therapy for solid tumors, tested in Phase 3 for ovarian cancer (OVAL trial) but failed to meet primary endpoints in 2022. ◦ VB-601: A monoclonal antibody for immune-inflammatory diseases, sold to ImmuneWalk Therapeutics in 2023. • History: ◦ 2000–2015: Developed VB-111, showing promise in Phase 2 trials for glioblastoma and ovarian cancer. ◦ 2018–2022: Phase 3 trials (GLOBE for glioblastoma, OVAL for ovarian cancer) failed to show significant benefits. ◦ 2023: Merged with Notable Labs, shifting focus to Notable’s precision medicine platform. VBL shareholders own ~24% of the combined company (NTBL). • Q4 Results: No specific Q4 financial data is available post-merger. Pre-merger, VBL focused on R&D, with no revenue from product sales and significant losses due to clinical trial costs. • Current Status: Post-merger, VBL’s legacy programs are deprioritized, and the combined company (Notable Labs) focuses on cancer precision medicine. Clarification Needed • Which VBL? Please confirm if you meant Varun Beverages Ltd or VBL Therapeutics. • Q4 Specificity: If you have access to VBL’s Q4 2024 results (e.g., from BSE or SEC filings), I can provide a more detailed analysis if you share key figures. • Fundamental Analysis Depth: Do you want a deeper dive into financial ratios, competitive positioning, or market outlook for Varun Beverages? For now, I recommend checking Varun Beverages’ investor relations page (https://varunpepsi.com) or Notable Labs’ website (https://notablelabs.com) for the latest Q4 data. If you clarify the company or provide specific financials, I can refine the response!